European Panel Backs Carfilzomib Label Update in Myeloma

April 30, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended adding final overall survival (OS) data from the phase III ASPIRE trial to the label for carfilzomib for the treatment of patients with relapsed/refractory multiple myeloma. In ASPIRE, the combination of carfilzomib, lenalidomide, and dexamethasone reduced the risk of death by 21% compared with lenalidomide and dexamethasone alone for … (leggi tutto)